Wu, H., Liu, L., Liu, S., Chai, X., Qiu, J., Zhang, Y., Zhang, Y., Wu, G., Zeng, Y., Wang, J., Zha, Y., Huang, B., Wu, F., Zheng, J., Lan, Y., Lv, B., Wu, L., Xu, R., Zhang, A., Zhu, A. X. (2026). Nilvanstomig (ZG005), an anti-PD-1/TIGIT bispecific antibody, plus bevacizumab vs. sintilimab plus bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma: A randomized, multi-center, phase II trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4014